الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 188 |  |  |
| | | from | 188 | | |
Abstract
The aim of this work is to investigate the effect of intravitreal and systemic squalamine, as an anti-antigenic AEW drug ,in an experimental model of intraocular neovascularization.this is to determine whether the induced iris revascularization in monkey eyes can be prevented or improved by squealing therapy.
Our study shows promising results of systemic squealing in the prevention and treatment of iris revascularization in non-human primates.intravitreal injections of squealing were not successful in preventing iris revascularization. This justifies further investigation of squealing as potential therapy for human ocular diseases involving angiogenesis
Intraocular neovascularization, or pathologic new vessel growth within the eye, causes morbidity in a number of eye diseases, including diabetic retinopathy, macular degeneration, and neovascular glaucoma. Neovascularization leads to hemorrhage and fibrosis and results in structural damage within the eye and subsequent visual loss. In developed countries, retinal neovascularization resulting from diabetic retinopathy is the most common cause of new blindness in young patients and choroidal neovascularization (CNV) resulting from age-related macular degeneration (AMD) is the most common cause of severe vision loss in elderly Therapy of ocular neovascularizing diseases is still unsatisfactory. Laser destruction of the non-perfused retina is the only established therapy to obliterate’ newly formed vessels. The discouraging natural course and the outcome of laser treatment, cryotherapy and vitreous surgery increase the demand to search for new treatments for these devastating diseases. During the last decade, new therapeutic approaches have been forwarded, including photodynamic ’therapy, surgical removal of CNV, radiotherapy of CNV, and medical treatments such as interferon, thalidomide and steroids. There are many eyes with intraocular neovascularization which are not suitable for laser photocoagulation, photodynamic therapy or radiotherapy because of cloudy media. Such patients require surgery or run the risk of complications related to neovascularization while they wait for the media to clear. Pharmacologic treatment for intraocular neovascularization would, therefore, be a major benefit to patients with ischemic retinopathies.